The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs
The DOI matches its Crossref record.
Abstract
BACKGROUND: Approximately 50% of patients diagnosed with major depressive disorder will experience a recurrent or chronic course of illness for which long-term treatment is recommended. Moreover, at least 20% of patients diagnosed with depression do not respond satisfactorily to several traditional antidepressant medication treatment trials. Very little is known about the health care costs of patients with treatment-resistant depression. METHOD: Based on medical claims data (MarketScan Research Database, The MEDSTAT Group, Cambridge, Mass.) from January 1, 1995, to June 30, 2000, a naturalistic, retrospective analysis was conducted to study the characteristics and health care utilization of patients with treatment-resistant depression. All patients having an International Classification of Diseases, Ninth Revision (ICD-9), diagnosis code for unipolar or bipolar depression with specified antidepressant dosing and treatment durations were initially selected. Patients were then classified as "treatment resistant" if either they switched from or augmented initial antidepressant medication with other antidepressants at least twice (outpatient treatment-resistant group) or they switched from or augmented their initial antidepressant medication and also had a claim for either a depression-related hospitalization or suicide attempt (hospitalized treatment-resistant group). Those meeting the initial medication and diagnosis selection criteria but not meeting the treatment-resistance criteria constituted the comparison group. Members of the comparison group had comparatively stable antidepressant medication use patterns, consistent with an acceptable response to treatment. Patients were followed for a minimum of 9 months. Resource utilization was calculated from index date to last available claims data point and then annualized. RESULTS: Treatment-resistant patients were more likely to be diagnosed with bipolar disorder or concurrent substance abuse or anxiety disorders than the comparison group (p <.001). Treatment-resistant patients were at least twice as likely to be hospitalized (general medical and depression related) and had at least 12% more outpatient visits (p <.02). Treatment resistance was also associated with use of 1.4 to 3 times more psychotropic medications (including antidepressants) (p <.001). Patients in the hospitalized treatment-resistant group had over 6 times the mean total medical costs of non-treatment-resistant depressed patients ($42,344 vs. $6512) (p <.001) and their total depression-related costs were 19 times greater than those of patients in the comparison group ($28,001 vs. $1455) (p <.001). CONCLUSION: Treatment-resistant depression is costly and associated with extensive use of depression-related and general medical services. These findings underscore the need for early identification and effective long-term maintenance treatment for treatment-resistant depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, for approximately 50% of those who suffer from depression, their illness will follow a chronic, relapsing course associated with considerable disability and impairment (Crown 2002).”
From Interventions for preventing relapse and recurrence of a depressive disorder in children and adolescents (2012) · cites this paper as Crown 2002
In the citing paper
“Direct medical costs associated with TRD are estimated to be 2-6 times higher compared with other patients with MDD, 42, 43 with costs increasing with chronicity and severity of TRD. 44”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [43]
In the citing paper
“Patients with TRD are twice as likely to be hospitalised compared with non-TRD patients, and require increased numbers of psychiatric outpatient visits. 43”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [43]
Citations
Cited by
Items 101–200 of 382
Chen, L., Klooster, D., Tik, M., Thomas, E. H. X., Downar, J. H., Fitzgerald, P. B., Williams, N., & Baeken, C. (2023) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000364 · Cited by 67
Guinjoan, S. M., Mayberg, H. S., Costanzo, E. Y., Fahrer, R. D., Tenca, E., Antico, J., Cerquetti, D., Smyth, E., Leiguarda, R. C., & Nemeroff, C. B. (2010) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.22.3.265 · Cited by 56
Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan
Fife, D., Feng, Y., Wang, M. Y.-H., Chang, C.-J., Liu, C.-Y., Juang, H.-T., Furnback, W., Singh, J., & Wang, B. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.03.006 · Cited by 55
Treatment-Resistant Depression Increases Health Costs and Resource Utilization
Lepine, B. A., Moreno, R. A., Campos, R. N., & Couttolenc, B. F. (2012) · Revista Brasileira de Psiquiatria · doi:10.1016/j.rbp.2012.05.009 · Cited by 54
Mathew, S. J., Wilkinson, S. T., Altinay, M., Asghar-Ali, A., Chang, L. C., Collins, K. A., Dale, R. M., Hu, B., Krishnan, K., Kellner, C. H., et al. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.12.009 · Cited by 54
Anxiety, depression and associated factors among recently divorced individuals
Hald, G. M., Ciprić, A., Sander, S., & Strizzi, J. M. (2020) · Journal of Mental Health · doi:10.1080/09638237.2020.1755022 · Cited by 88
“Both depression and anxiety have been linked with various adverse health outcomes including substance use (Hallfors et al., 2004), lower self-efficiency (Gilmour & Patten, 2007; Lovejoy et al., 2000), chronic illness (Crown et al., 2002; Suls & Bunde, 2005) and suicide (Hallfors et al., 2004).”
BackgroundBrunner, E., Tohen, M., Osuntokun, O., Landry, J., & Thase, M. E. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.101 · Cited by 49
“In contrast to depressed persons without TRD, patients with TRD are at least twice as likely to be hospitalized, are prescribed up to three times as many psychotropic medications, and have higher medical costs owing to polypharmacy (Crown et al, 2002; Greden, 2001).”
BackgroundRoss, E. L., Vijan, S., Miller, E. M., Valenstein, M., & Zivin, K. (2019) · Annals of Internal Medicine · doi:10.7326/m18-1480 · Cited by 50
“Other health care costs were derived from 2 studies that used MarketScan insurance claims data to estimate aggregate costs for people with depression, stratified by number of prior treatments (30, 41).”
Cox, G. R., Fisher, C. A., De Silva, S., Phelan, M., Akinwale, O. P., Simmons, M. B., & Hetrick, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007504.pub2 · Cited by 48
Mahlich, J., Tsukazawa, S., & Wiegand, F. (2018) · Drugs - Real World Outcomes · doi:10.1007/s40801-017-0126-5 · Cited by 49
Olfson, M., Amos, T. B., Benson, C., McRae, J., & Marcus, S. C. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.3.226 · Cited by 48
Sikkens, D., Riemersma - Van der Lek, R. F., Meesters, Y., Schoevers, R. A., & Haarman, B. C. M. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.12.117 · Cited by 48
Kishimoto, T., Hagi, K., Kurokawa, S., Kane, J., & Correll, C. (2022) · Psychological Medicine · doi:10.1017/s0033291722000745 · Cited by 34
“Approximately 5 – 12% of males and 9 – 26% of females will suffer from at least one episode of MDD over their lifetime, and about 50% of patients will experience a second depressive episode (Crown et al., 2002; Finley, 2009; Kessler et al., 2003).”
Solomon, D., Adams, J., & Graves, N. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.11.064 · Cited by 55
Huber, C. G., Naber, D., & Lambert, M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.12.2027 · Cited by 46
“Finally, 80 – 90% of those having experienced two or more episodes will have further recurrences [47] .”
BackgroundDeep brain stimulation in mental health: Review of evidence for clinical efficacy
Fitzgerald, P. B., & Segrave, R. A. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415598011 · Cited by 54
“The economic burden is also considerable with the treatment costs for treatment non-responsive patients up to 19 times greater than those for patients with depression who respond to treatment (Crown et al., 2002).”
BackgroundRhoads, G. G., Orsini, L. S., Crown, W., Wang, S., Getahun, D., & Zhang, Q. (2005) · Journal of Occupational and Environmental Medicine · doi:10.1097/01.jom.0000161727.03431.3e · Cited by 46
Self-citationConway, C. R., Aaronson, S. T., Sackeïm, H. A., George, M. S., Zajecka, J., Bunker, M. T., Duffy, W. J., Stedman, M., Riva‐Posse, P., Allen, R. M., et al. (2024) · Brain stimulation · doi:10.1016/j.brs.2024.12.1191 · Cited by 57
“Greater “ treatment resistance ” is associated with more suicide attempts [4], hospitalizations [5], disability [2], health care/- societal costs [6,7], and lower likelihood of sustained responses or remission [8 – 10].”
Self-citationGao, K., Wang, Z., Chen, J., Kemp, D. E., Chan, P. K., Conroy, C. M., Serrano, M. B., Ganocy, S. J., & Calabrese, J. R. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.12.004 · Cited by 51
Propoxyphene use and risk for hip fractures in older adults
Kamal‐Bahl, S. J., Stuart, B., & Beers, M. H. (2006) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2006.09.005 · Cited by 43
Advances in Brain Stimulation for Depression
Wani, A., Trevino, K., Marnell, P., & Husain, M. M. (2013) · Annals of Clinical Psychiatry · doi:10.1177/104012371302500308 · Cited by 42
Attali, D., Tiennot, T., Manuel, T. J., Daniel, M., Houdouin, A., Annic, P., Dizeux, A., Haroche, A., Dadi, G., Henensal, A., et al. (2025) · Brain stimulation · doi:10.1016/j.brs.2025.04.018 · Cited by 48
“Drug resistance leads to a substantial increase in morbidity and in healthcare burden and costs, up to ten times higher than for non-resistant patients [3,4].”
Burden of Illness in Bipolar Depression
Manning, J. S. (2005) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v07n0601 · Cited by 45
Lambert, M., Terrell, J. E., Copeland, L. A., Ronis, D. L., & Duffy, S. A. (2005) · Nicotine & Tobacco Research · doi:10.1080/14622200500055418 · Cited by 44
“…1997), despite evidence that treatment improves medical outcomes and quality of life and reduces costs (Cassano & Fava, 2002; Creed et al., 2002; Crown et al., 2002; Katon & Ciechanowski, 2002; Lave, Frank, Schulberg, & Kamlet, 1998; Terrell, Nanavati, Esclamado, Bradford, & Wolf, 1999;…”
BackgroundEEG gamma synchronization is associated with response to paroxetine treatment
Arikan, M. K., Metin, B., & Tarhan, N. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.04.041 · Cited by 39
Sun, J., Ma, Y., Guo, C., Du, Z., Chen, L., Wang, Z., Li, X., Xu, K., Luo, Y., Yang, H., et al. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110621 · Cited by 47
Chen, Y., Liu, & Faries (2011) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s17846 · Cited by 38
Burke, M. J., & Husain, M. M. (2006) · Journal of Ect · doi:10.1097/01.yct.0000230364.04240.52 · Cited by 44
“Treatment-resistant depression is an all too common condition affecting up to 30% of patients with depression and is associated with increased morbidity and mortality.(4,5) Management of TRD has been particularly frustrating for both patients and clinicians who recognize the need for more effective, long-term treatmen…”
BackgroundDoes Neurotropin-3 Have a Therapeutic Implication in Major Depression?
Pae, C., Marks, D. M., Han, C., Patkar, A. A., & Steffens, D. C. (2008) · International Journal of Neuroscience · doi:10.1080/00207450802174589 · Cited by 41
“Despite antidepressants being the gold standard for the treatment of depression, only one third of patients treated with an antidepressant completely recover from their functional impairment (Crown et al., 2002).”
BackgroundLynch, T. R., Hempel, R. J., Whalley, B., Byford, S., Chamba, R., Clarke, P., Clarke, S., Kingdon, D. G., O'Mahen, H., Remington, B., et al. (2020) · The British Journal of Psychiatry · doi:10.1192/bjp.2019.53 · Cited by 38
Oliveira-Maia, A. J., Bobrowska, A., Constant, É., Ito, T., Kambarov, Y., Luedke, H., Mulhern-Haughey, S., & von Holt, C. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02700-0 · Cited by 57
“Furthermore, the burden of TRD increases with the duration of the disorder, culminating in rates of hospitalisation for general medical and depression-related causes that are double those reported in patients with treatment-responsive MDD [12, 13].”
Antidepressant drug development: Focus on triple monoamine reuptake inhibition
Lane, R. M. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114553252 · Cited by 44
“MDD not responding adequately to treatment is a common clinical presentation and is responsible for much of the staggering disability and cost associated with MDD (Crown et al., 2002; Fekadu et al., 2009; Fostick et al., 2010; Greden, 2001; Souery et al., 2006).”
BackgroundHowland, R. H. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5453 · Cited by 42
Hsu, T., Yeh, T., Kao, Y., Thompson, T., Brunoni, A. R., Carvalho, A. F., Hsu, C.-W., Tu, Y., & Liang, C. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105704 · Cited by 40
Healthcare and economic impact of diarrhea in patients with carcinoid syndrome
Broder, M. S., Chang, E., Romanus, D., Cherepanov, D., & Neary, M. P. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i6.2118 · Cited by 43
Dennehy, E. B., Robinson, R. L., Stephenson, J. J., Faries, D., Grabner, M., Palli, S. R., Stauffer, V. L., & Marangell, L. B. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1029893 · Cited by 37
Number of risk genotypes is a risk factor for major depressive disorder: a case control study
Garriock, H. A., Delgado, P., Kling, M. A., Carpenter, L. L., Burke, M., Burke, W. J., Schwartz, T., Marangell, L. B., Husain, M., Erickson, R. P., et al. (2006) · Behavioral and Brain Functions · doi:10.1186/1744-9081-2-24 · Cited by 37
Amital, D., Fostick, L., Silberman, A., Calati, R., Spindelegger, C., Serretti, A., Juven‐Wetzler, A., Souery, D., Mendlewicz, J., Montgomery, S., et al. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.09.002 · Cited by 37
“(Glassman et al, 1975; Schatzberg and Rothschild, 1992), substance abuse, bipolar disorder (Berlim & Turecki, 2007; Crown et al., 2002), anxiety (Berlim & Turecki, 2007; Crown et al.”
InfluentialRoy, A. V., Thai, M., Klimes‐Dougan, B., Schreiner, M. W., Mueller, B. A., Albott, C. S., Lim, K. O., Fiecas, M. J. A., Tye, S. J., & Cullen, K. R. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120928203 · Cited by 39
“Such treatment-resistant depression (TRD) is associated with poor outcomes, including academic failure, loss of relationships, and exacerbation of depression symptoms such as poor self-esteem, hopelessness and suicide attempts (Asarnow et al., 2011; Crown et al., 2002; Greden, 2001).”
BackgroundLee, Y.-J., Lee, G.-W., Seo, W. S., Koo, B., Kim, H.-G., & Cheon, E. (2019) · Journal of Korean Medical Science · doi:10.3346/jkms.2019.34.e287 · Cited by 41
Blumentals, W. A., & Schulman, K. L. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x242520 · Cited by 34
The economic cost of treatment-resistant depression in patients referred to a specialist service
McCrone, P., Rost, F., Koeser, L., Koutoufa, I., Stephanou, S., Knapp, M., Goldberg, D., Taylor, D., & Fonagy, P. (2018) · Journal of Mental Health · doi:10.1080/09638237.2017.1417562 · Cited by 33
“These patients have also been found to make a disproportionate contribution to the economic burden associated with the spectrum of depressive disorders (Crown et al., 2002; Ivanova et al., 2010).”
A sham-controlled randomized trial of adjunctive light therapy for non-seasonal depression
Chojnacka, M., Antosik-Wójcińska, A. Z., Dominiak, M., Bzinkowska, D., Borzym, A., Sokół-Szawłowska, M., Bodzak-Opolska, G., Antoniak, D., & Święcicki, Ł. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.05.062 · Cited by 32
Havlik, J. L., Wahid, S., Teopiz, K. M., McIntyre, R. S., Krystal, J. H., & Rhee, T. G. (2024) · Current Psychiatry Reports · doi:10.1007/s11920-024-01494-4 · Cited by 37
Shin, D., Kim, N. W., Kim, M. J., Rhee, S. J., Park, C. H. K., Kim, H.-Y., Yang, B. R., Kim, M.-S., Choi, G., Koh, M., et al. (2020) · BMC Health Services Research · doi:10.1186/s12913-020-05153-1 · Cited by 34
“TRD patients are known to frequently use antipsychotics, nonpharmaceutical treatments, and inpatient treatment [16] and are often associated with multiple episodes of depression, decreased quality of life, and increased mortality [17].”
BackgroundAdekkanattu, P. M., Olfson, M., Susser, L. C., Patra, B. G., Vekaria, V., Coombes, B. J., Lepow, L., Fennessy, B., Charney, A. W., Ryu, E., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.12.044 · Cited by 46
Treatment-Resistant Depression in Poland—Epidemiology and Treatment
Gałecki, P., Samochowiec, J., Mikułowska, M., & Szulc, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030480 · Cited by 39
“TRD patients generate higher medical costs (both direct and indirect) than MDD patients who are responsive to treatment; these costs increase with TRD severity [2,12,22,23].”
BackgroundInfluentialBirnbaum, H. G., Ben-Hamadi, R., Greenberg, P. E., Hsieh, M., Tang, J., & Reygrobellet, C. (2009) · PharmacoEconomics · doi:10.2165/00019053-200927060-00006 · Cited by 31
Predictors of repeated sick leave in the workplace because of mental disorders
Sado, M., Shirahase, J., Yoshimura, K., Miura, Y., Yamamoto, K., Tabuchi, H., Kato, M., & Mimura, M. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s55490 · Cited by 36
“This result is consistent with the findings of previous studies, 24–27 which showed that a larger number of previous episodes were associated with a higher risk of relapse/recurrence.”
Keks, N. A., Burrows, G. D., Copolov, D., Newton, R., Paoletti, N., Schweitzer, I., & Tiller, J. W. G. (2007) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2007.tb00838.x · Cited by 31
Ketamine: stimulating antidepressant treatment?
Malhi, G. S., Byrow, Y., Cassidy, F., Cipriani, A., Demyttenaere, K., Frye, M. A., Gitlin, M., Kennedy, S. H., Ketter, T. A., Lam, R. W., et al. (2016) · BJPsych Open · doi:10.1192/bjpo.bp.116.002923 · Cited by 29
Rao, D., Xu, G., Lu, Z., Liang, H., Lin, K., & Tang, M. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s226405 · Cited by 29
“About 20% of depressive patients do not respond satisfactorily, and roughly half will experience a chronic or recurrent course of illness.(3,4)”
BackgroundPae, C., Lee, C., & Paik, I. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.11.009 · Cited by 29
Maughan‐Brown, B., Lloyd, N., Bor, J. H., & Venkataramani, A. S. (2016) · Journal of the International AIDS Society · doi:10.7448/ias.19.1.20658 · Cited by 29
“Given that poor mental health and substance use may act as barriers to health service utilization [30,31], we also included a measure of depression (based on the Center for Epidemiologic Studies Depression Scale) [32] and a binary indicator of alcohol consumption.”
MethodTreatment of depression in patients with epilepsy: problems, pitfalls, and some solutions
Krishnamoorthy, E. S. (2003) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2003.08.017 · Cited by 30
What Is the Role of Brain Stimulation Therapies in the Treatment of Depression?
Blumberger, D. M., Mulsant, B. H., & Daskalakis, Z. J. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-013-0368-1 · Cited by 32
Regulation of Antidepressant Activity by cAMP Response Element Binding Proteins
Conti, A. C., & Blendy, J. A. (2004) · Molecular Neurobiology · doi:10.1385/mn:30:2:143 · Cited by 30
Sex differences in frequent ED use among those with multimorbid chronic diseases
Milani, S. A., Crooke, H. R., Cottler, L. B., & Striley, C. W. (2016) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2016.07.059 · Cited by 33
Medication Options in the Treatment of Treatment-Resistant Depression
PRIDMORE, S. A., & Turnier‐Shea, Y. (2004) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2004.01335.x · Cited by 30
“Approximately 50% of patients diagnosed with major depressive disorder will experience a recurrent or chronic course for which long-term treatment is recommended [19].”
BackgroundLin, C., Lin, S., & Jang, F.-L. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31822bb0db · Cited by 31
“(J Clin Psychopharmacol 2011;31: 563Y568) The Sequenced Treatment Alternatives to Relieve Depression study showed high prevalence of treatment-resistant depression (TRD),(1) which is associated with higher rates of relapse and recurrence, poorer quality of life, increased mortality, higher health care use, and higher…”
BackgroundPrevalence and comorbidity of major depressive disorder in young black and white women
Franko, D. L., Thompson, D., BARTON, B. A., Dohm, F., KRAEMER, H. C., Iachan, R., Crawford, P. B., Schreiber, G. B., Daniels, S. R., & Striegel‐Moore, R. H. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.08.010 · Cited by 31
“Furthermore, studies have found poorer outcomes in those with multiple disorders, including higher use of health services, more disability, greater functional impairment, and increased suicidality (Crown et al., 2002; DeBernardo et al., 2002; Kirchner et al., 2002).”
Plakun, E. M. (2006) · Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry · doi:10.1521/jaap.2006.34.2.349 · Cited by 32
Mondimore, F. M., Zandi, P. P., MacKinnon, D. F., McInnis, M. G., Miller, E. B., Schweizer, B. W., Crowe, R., Scheftner, W. A., Weissman, M. M., Levinson, D. F., et al. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.10.011 · Cited by 29
“…and impairment than patients with non-chronic depressive illness and have been found to have increased rates of substance abuse and anxiety disorders (Crown et al., 2002) of attempted suicide (Klein et al., 2000), and substantial psychosocial and socioeconomic disability (Kennedy and Paykel, 2004).”
BackgroundEscitalopram: A Pharmacoeconomic Review of its Use in Depression
Croom, K. F., & Plosker, G. L. (2003) · PharmacoEconomics · doi:10.2165/00019053-200321160-00004 · Cited by 41
The Individual and Societal Burden of Treatment-Resistant Depression
Baig-Ward, K. M., Jha, M. K., & Trivedi, M. H. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.001 · Cited by 47
Ershadi, A. S. B., Amini-Khoei, H., Hosseini, M.-J., & Dehpour, A. R. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03263-8 · Cited by 25
Shah, D., Allen, L., Zheng, W., Madhavan, S., Wei, W., LeMasters, T. J., & Sambamoorthi, U. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01029-2 · Cited by 27
“This is consistent with reports obtained from previous studies conducted among adults with MDD [16, 22, 23].”
ResultLee, C. T., Palacios, J., Richards, D., Hanlon, A. K., Lynch, K., Harty, S., Claus, N., Swords, L., O’Keane, V., Stephan, K. E., et al. (2023) · BMC Psychiatry · doi:10.1186/s12888-022-04462-5 · Cited by 25
“This leads to sustained human suffering, accumulation of side-effects, and substantial economic costs [5, 6].”
BackgroundRicka, N., Pellegrin, G., Fompeyrine, D. A., Lahutte, B., & Geoffroy, P. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-33359-w · Cited by 28
Yu, Z. J., Weller, R. A., Sandidge, K., & Weller, E. B. (2008) · Current Psychiatry Reports · doi:10.1007/s11920-008-0021-6 · Cited by 26
Roth‐Deri, I., Friedman, A., Abraham, L., Lax, E., Flaumenhaft, Y., Dikshtein, Y., & Yadid, G. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06840.x · Cited by 27
“An additional study has indicated that patients with treatment-resistant depression were more likely to be diagnosed with concurrent substance misuse disorder (Crown et al., 2002).”
BackgroundReal world efficacy and safety of various accelerated deep TMS protocols for major depression
Roth, Y., Hanlon, C. A., Pell, G. S., Zibman, S., Harmelech, T., Muir, O. S., MACMILLAN, C. M., Prestley, T., Purselle, D. C., Knightly, T., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115482 · Cited by 30
“While many pharmacotherapeutic options are available, up to 30% of patients with MDD do not respond well to pharmacotherapy (Crown et al., 2002; Rush et al., 2006).”
BackgroundOptimized light therapy for non-seasonal major depressive disorder: Effects of timing and season
Dallaspezia, S., Benedetti, F., Colombo, C., Barbini, B., Fulgosi, M. C., Gavinelli, C., & Smeraldi, E. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.01.019 · Cited by 31
“In everyday clinical practice antidepressant drugs are the mainstay for the treatment of depression, but treatment efficacy is lower than desired: at least 40% of patients do not respond to the initial trial of antidepressant medication, and at least one half of this percentage do not respond to further treatment tria…”
BackgroundPsychotherapy in recurrent depression: efficacy, pitfalls, and recommendations
Cosci, F., Guidi, J., Mansueto, G., & Fava, G. A. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1804870 · Cited by 31
Kishida, I., Aklillu, E., Kawanishi, C., Bertilsson, L., & Ågren, H. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301336 · Cited by 25
Electroconvulsive therapy for major depression within the Veterans Health Administration
Pfeiffer, P. N., Valenstein, M. M., Hoggatt, K. J., Ganoczy, D. A., Maixner, D. F., Miller, E. M., & Zivin, K. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.09.023 · Cited by 24
“…veterans were less likely to receive ECT than older veterans, consistent with prior reports of ECT use in the US and with studies showing that patients with treatment resistant depression are older than other depressed patients (Crown et al., 2002; Kramer, 1997; Thompson and Blaine, 1987).”
Epidemiology of treatment resistant depression among major depressive disorder patients in Israel
Sharman Moser, S., Chodick, G., Gelerstein, S., Barit Ben David, N., Shalev, V., & Stein-Reisner, O. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04184-8 · Cited by 23
“Treatment resistant depression (TRD) is associated with increased health care utilization and cost with at least 12% more outpatient visits, increased use of psychotropic medications and double the risk of hospitalization than other patients suffering from MDD [13].”
BackgroundYu, C., Kao, Y., Thompson, T., Brunoni, A. R., Hsu, C., Carvalho, A. F., Chu, C., Tseng, P., Tu, Y., Yang, F., et al. (2023) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2023.103891 · Cited by 29
Advances in the Management of Treatment-Resistant Depression
Holtzheimer, P. E. (2010) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.8.4.foc488 · Cited by 29
“Continued depressive symptoms are associated with ongoing functional impairment (2), increased usage of health care resources (3), a greater risk of suicide (4–6), and overall increased mortality, especially associated with cardiovascular disease (7–10).”
BackgroundKeks, N. A., Burrows, G. D., Copolov, D., Newton, R., Paoletti, N., Schweitzer, I., & Tiller, J. W. G. (2007) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2007.tb01194.x · Cited by 23
Radically open dialectical behaviour therapy for refractory depression: the RefraMED RCT
Lynch, T. R., Hempel, R. J., Whalley, B., Byford, S., Chamba, R., Clarke, P., Clarke, S., Kingdon, D., O’Mahen, H., Remington, B., et al. (2018) · Efficacy and Mechanism Evaluation · doi:10.3310/eme05070 · Cited by 22
“Approximately 50% of patients who are diagnosed with major depressive disorder experience recurrent or chronic illness needing long-term treatment.(7) Those with chronic depression are least likely to respond to currently available treatments.”
BackgroundSun, J., Ma, Y., Chen, L., Wang, Z., Guo, C., Luo, Y., Gao, D., Li, X., Xu, K., Yang, H., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.904139 · Cited by 26
“Overall medical costs for TRD patients are almost twice or more than twice as high as those for nTRD patients (8, 9).”
BackgroundPrefrontal dysfunction in remitted depression at work reinstatement using near-infrared spectroscopy
Ikeda, E., Shiozaki, K., Ikeda, H., Suzuki, M., & Hirayasu, Y. (2013) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2013.07.009 · Cited by 22
“The recurrence rate of mental disorders is assumed to be high (Mueller et al., 1999; Crown et al., 2002; Keller, 2002; Yonkers et al., 2003; Robinson and Sahakian, 2008) and employees with a previous episode of sickness absence with common mental disorders are at increased risk of recurrent sickness absence (Koopmans…”
BackgroundOlanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility
Dodd, S., & Berk, M. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.9.1299 · Cited by 22
Bouhuys, A. L., Bos, E. H., Geerts, E., van Os, T. W. D. P., & Ormel, J. (2006) · Journal of Nervous & Mental Disease · doi:10.1097/01.nmd.0000228502.52864.ce · Cited by 22
“(J Nerv Ment Dis 2006;194: 478–484) Recurrence rates of depression after recovery are high,incurring considerable social and financial costs (Angst, 1999; Crown et al., 2002; Pincus and Pettit, 2001).”
BackgroundImmune System Contributions to the Pathophysiology of Depression
Miller, A. H., & Raison, C. L. (2008) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.6.1.foc36 · Cited by 33
Potential of St John's Wort for the Treatment of Depression: The Economic Perspective
Solomon, D., Ford, E., Adams, J., & Graves, N. (2010) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048674.2010.526094 · Cited by 21
“Previous cost analyses of drug treatment for depression have highlighted the signifi cance of the cost of ‘ treatment resistance ’ or ‘ treatment failure ’ on the expected cost of treatment [11,12].”
BackgroundPilon, D., Sheehan, J. J., Szukis, H., Morrison, L., Zhdanava, M., Lefèbvre, P., & Joshi, K. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.100 · Cited by 24
Sun, J., Ma, Y., Du, Z., Wang, Z., Guo, C., Luo, Y., Chen, L., Gao, D., Li, X., Xu, K., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.923783 · Cited by 28
“The acquired rs-fMRI data were preprocessed using MATLABbased DPARSF 5.1 software (DPARSF 5.11) (38), as follows: 1http://www.rfmri.org/DPARSF (1) conversion of DICOM raw data to NIFTI format; (2) removal of the first 10 time points to stabilize the data; (3) slice timing; (4) realignment of head motion (removal of pa…”
MethodInfluentialVieira, W. F., Iosifescu, D. V., McEachern, K. M., Gersten, M. B., & Cassano, P. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.013 · Cited by 26
Lin, Z., He, H., Zhang, C., Wang, Z., Jiang, M., Li, Q., Lan, X., Zhang, M., & Huang, X. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0361-2 · Cited by 21
“Clinical manifestation of TRD includes suicidal behavior, low self-assessment, sense of guilt, anxiety and irritability, loss of appetite, and insomnia [5, 10, 29].”
BackgroundPatterns of Initial Pharmacotherapy for Parkinson’s Disease in the United States
Huse, D. M., Castelli‐Haley, J., Orsini, L. S., Lenhart, G. M., & Abdalla, J. A. (2006) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988706286512 · Cited by 22
Bobo, W. V., & Shelton, R. C. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.44 · Cited by 24
Li, C., Bai, Y., Lee, Y.-C., Mao, W., Chen, M., Tu, P., Chen, Y.-S., Chen, T., Chang, W.-H., & Su, T. (2014) · SLEEP · doi:10.5665/sleep.3594 · Cited by 23
Do Antidepressants Reduce the Burden Imposed by Depression on Employers?
Greener, M., & Guest, J. F. (2005) · CNS Drugs · doi:10.2165/00023210-200519030-00006 · Cited by 28
Never Too Late: Safety and Efficacy of Deep TMS for Late-Life Depression
Roth, Y., Munasifi, F., Harvey, S. A., Grammer, G. G., Hanlon, C. A., & Tendler, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030816 · Cited by 24
“Yet, about 30% of patients with MDD do not respond well to pharmacotherapy [4,5], including adults with late-life depression [6].”
BackgroundLok, A., Mocking, R. J. T., Assies, J., Koeter, M. W. J., Bockting, C., de Vries, G., Visser, I., Derks, E. M., Kayser, M., & Schene, A. H. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.04.048 · Cited by 25
Giacobbe, P., Mithani, K., Meng, Y., Vila‐Rodriguez, F., Daskalakis, Z. J., Downar, J. H., & Blumberger, D. M. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.002 · Cited by 26
Recurrence of major depressive disorder is predicted by inhibited startle magnitude while recovered
O’Brien-Simpson, L., Parsia, P. D., Simmons, J. G., & Allen, N. B. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.03.022 · Cited by 19
“For approximately 50% of those who suffer from depression their illness will follow a chronic, relapsing course associated with considerable disability and impairment (Crown et al., 2002).”
BackgroundOrsini, L. S., Limpa-Amara, S., Crown, W. H., Stanford, R. H., & Kamal, K. M. (2004) · Annals of Allergy Asthma & Immunology · doi:10.1016/s1081-1206(10)61759-0 · Cited by 20
Self-citation
Metadata
- Authors
- Crown, W. H., Finkelstein, S., Berndt, E. R., Ling, D., Poret, A. W., Rush, A. J., & Russell, J. M.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2002-11-15
- Volume
- 63
- Issue
- 11
- Pages
- 963-971
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2098750661
- Cited by
- 386
- References
- 0
- Citations by year
- 2026: 16 · 2025: 13 · 2024: 13 · 2023: 23 · 2022: 20 · 2021: 17 · 2020: 17 · 2019: 18 · 2018: 16 · 2017: 9 · 2016: 15 · 2015: 17 · 2014: 19 · 2013: 19 · 2012: 17
- FWCI
- 6.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- treatment-resistant depression, major depressive disorder, bipolar disorder, health care utilization, health care costs, antidepressants, hospitalization, psychotropic drug use, substance use comorbidity, anxiety disorders, health insurance claims data, suicide attempts, outpatient visits, chronic depression, recurrent depression
- MeSH terms
- Adult, Ambulatory Care, Bipolar Disorder, Costs and Cost Analysis, Depressive Disorder, Major, Major Depressive Disorder, Drug Resistance, Female, Humans, Male, Middle Aged, Patient Acceptance of Health Care, Patient Admission, Psychotropic Drugs, Referral and Consultation, Retrospective Studies, Utilization Review, Comorbidity, Drug Costs, Health Care Costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.